NX-5948 combined with other medicines for chronic lymphocytic leukemia and B-cell lymphoma
Tests NX-5948 with venetoclax in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Plain-language title generated from the registry record
Registry title: Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Key facts
- Where
- Aurora, Belleville, Coral Gables, Eugene, Kansas City, Las Vegas, Nashville, Pittsburgh, and Tyler, United StatesSee the 9 sites
- Phase
- Phase 1/2
Where in United States
- Rocky Mountain Cancer CentersAurora, United StatesTaking people
- New Jersey Cancer CareBelleville, United StatesNot yet recruiting
- University of MiamiCoral Gables, United StatesNot yet recruiting
- Oncology Associates of OregonEugene, United StatesTaking people
- University of Kansas Cancer CenterKansas City, United StatesNot yet recruiting
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesNot yet recruiting
- SCRI Oncology PartnersNashville, United StatesTaking people
- UPMC Hillman Cancer CenterPittsburgh, United StatesTaking people
- Texas Oncology - NortheastTyler, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nurix Therapeutics, Inc.
- Trial code
- NCT07520006
- Record updated
- 3 November 2026
- Original description
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Read full original descriptionShow less
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Inclusion: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; Adequate organ and bone marrow function; Measurable disease by computed tomography (CT) per iwCLL; For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi); For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria; Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate.
Exclusion: Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment; Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation; Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast; Previously treated with a BTK degrader; Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment; Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment; Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment; Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol; Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment; Known central nervous system (CNS) lymphoma or leukemia.